- Home
- RLTY vs OMER Comparison
RLTY vs OMER Comparison
Compare RLTY & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- OMER
- Stock Information
- Founded
- RLTY 2022
- OMER 1994
- Country
- RLTY United States
- OMER United States
- Employees
- RLTY N/A
- OMER N/A
- Industry
- RLTY Investment Managers
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- OMER Health Care
- Exchange
- RLTY Nasdaq
- OMER Nasdaq
- Market Cap
- RLTY 256.4M
- OMER 221.4M
- IPO Year
- RLTY N/A
- OMER 2009
- Fundamental
- Price
- RLTY $17.05
- OMER $4.14
- Analyst Decision
- RLTY
- OMER Hold
- Analyst Count
- RLTY 0
- OMER 2
- Target Price
- RLTY N/A
- OMER N/A
- AVG Volume (30 Days)
- RLTY 86.7K
- OMER 216.3K
- Earning Date
- RLTY 01-01-0001
- OMER 11-07-2024
- Dividend Yield
- RLTY 9.35%
- OMER N/A
- EPS Growth
- RLTY N/A
- OMER N/A
- EPS
- RLTY N/A
- OMER N/A
- Revenue
- RLTY N/A
- OMER N/A
- Revenue This Year
- RLTY N/A
- OMER N/A
- Revenue Next Year
- RLTY N/A
- OMER N/A
- P/E Ratio
- RLTY N/A
- OMER N/A
- Revenue Growth
- RLTY N/A
- OMER N/A
- 52 Week Low
- RLTY $11.38
- OMER $1.05
- 52 Week High
- RLTY $14.60
- OMER $5.68
- Technical
- Relative Strength Index (RSI)
- RLTY 55.71
- OMER 57.87
- Support Level
- RLTY $16.22
- OMER $3.75
- Resistance Level
- RLTY $16.89
- OMER $4.24
- Average True Range (ATR)
- RLTY 0.29
- OMER 0.18
- MACD
- RLTY 0.01
- OMER 0.04
- Stochastic Oscillator
- RLTY 72.81
- OMER 79.59
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.